IL-11 as a Novel Target for Arthrofibrosis Therapy
Location
LSUHSC-NO Center for Advanced Learning and Simulation
Document Type
Presentation
Start Date
21-6-2025 10:20 AM
End Date
21-6-2025 11:15 AM
Publication Date
June 2025
Description
Introduction: Arthrofibrosis (AF) is a debilitating complication of joint trauma, surgery, or chronic conditions such as osteoarthritis (OA), often resulting in painful stiffness and restricted mobility. Standard treatments like manipulation under anesthesia (MUA) and arthrolysis are frequently inadequate in severe or refractory cases. Interleukin-11 (IL11), a downstream effector of TGF-β1, drives myofibroblast differentiation and pathological collagen deposition, as previously demonstrated in idiopathic pulmonary fibrosis (IPF). This study investigates the antifibrotic potential of novel small-molecule IL11 inhibitors (NMX compounds) in models of AF.
Methods: Primary fibroblasts were isolated from the knees of 24 patients with histologically graded low or high severity arthrofibrosis secondary to OA. Synovial fluid analyses revealed significantly elevated IL11 and collagen levels, correlating with fibrosis severity. Commercial human fibroblast-like synoviocytes were then treated with TGF-β1 to induce fibrotic activation in vitro. Cells were subsequently treated with NMX compounds, including NM1155 and NM1207. IL11 expression and fibrosis markers (αSMA, COL1) were quantified and compared across untreated, unstimulated, and treated groups.
Results: NMX treatment significantly suppressed IL11 expression and fibrotic markers in TGF-β1-stimulated synovial fibroblasts and patient-derived AF myofibroblasts. NM1155 effectively reduced αSMA-positive myofibroblast differentiation, while the next-generation compound NM1207, designed for improved half-life, demonstrated superior efficacy in decreasing COL1 production.
Discussion: IL11 plays a pivotal role in promoting myofibroblast persistence and collagen accumulation in AF, paralleling mechanisms observed in IPF. The ability of NMX compounds to blunt this fibrotic response highlights IL11 as a key therapeutic target. Correlations between IL11 levels, collagen burden, and disease severity further support its use as both a biomarker and intervention point in AF management.
Significance/Clinical relevance: These findings support IL11 inhibition as a promising, noninvasive therapeutic strategy for arthrofibrosis. NMX compounds may offer a disease-modifying alternative to surgery, potentially improving joint function and patient outcomes. Future in vivo studies will determine their translational applicability and long-term efficacy in AF.
Recommended Citation
De Jesus, Miguel A., "IL-11 as a Novel Target for Arthrofibrosis Therapy" (2025). Dept. of Orthopaedics: Robert D. D’Ambrosia Lectureship & Research Day. 7.
https://digitalscholar.lsuhsc.edu/ortho_rd/2025/presentation2/7
IL-11 as a Novel Target for Arthrofibrosis Therapy
LSUHSC-NO Center for Advanced Learning and Simulation
Introduction: Arthrofibrosis (AF) is a debilitating complication of joint trauma, surgery, or chronic conditions such as osteoarthritis (OA), often resulting in painful stiffness and restricted mobility. Standard treatments like manipulation under anesthesia (MUA) and arthrolysis are frequently inadequate in severe or refractory cases. Interleukin-11 (IL11), a downstream effector of TGF-β1, drives myofibroblast differentiation and pathological collagen deposition, as previously demonstrated in idiopathic pulmonary fibrosis (IPF). This study investigates the antifibrotic potential of novel small-molecule IL11 inhibitors (NMX compounds) in models of AF.
Methods: Primary fibroblasts were isolated from the knees of 24 patients with histologically graded low or high severity arthrofibrosis secondary to OA. Synovial fluid analyses revealed significantly elevated IL11 and collagen levels, correlating with fibrosis severity. Commercial human fibroblast-like synoviocytes were then treated with TGF-β1 to induce fibrotic activation in vitro. Cells were subsequently treated with NMX compounds, including NM1155 and NM1207. IL11 expression and fibrosis markers (αSMA, COL1) were quantified and compared across untreated, unstimulated, and treated groups.
Results: NMX treatment significantly suppressed IL11 expression and fibrotic markers in TGF-β1-stimulated synovial fibroblasts and patient-derived AF myofibroblasts. NM1155 effectively reduced αSMA-positive myofibroblast differentiation, while the next-generation compound NM1207, designed for improved half-life, demonstrated superior efficacy in decreasing COL1 production.
Discussion: IL11 plays a pivotal role in promoting myofibroblast persistence and collagen accumulation in AF, paralleling mechanisms observed in IPF. The ability of NMX compounds to blunt this fibrotic response highlights IL11 as a key therapeutic target. Correlations between IL11 levels, collagen burden, and disease severity further support its use as both a biomarker and intervention point in AF management.
Significance/Clinical relevance: These findings support IL11 inhibition as a promising, noninvasive therapeutic strategy for arthrofibrosis. NMX compounds may offer a disease-modifying alternative to surgery, potentially improving joint function and patient outcomes. Future in vivo studies will determine their translational applicability and long-term efficacy in AF.
Comments
Student and Fellow Presentation